KR102912248B1 - 신규 히드록시프로필-β-사이클로덱스트린 및 이의 제조 방법 - Google Patents

신규 히드록시프로필-β-사이클로덱스트린 및 이의 제조 방법

Info

Publication number
KR102912248B1
KR102912248B1 KR1020207037131A KR20207037131A KR102912248B1 KR 102912248 B1 KR102912248 B1 KR 102912248B1 KR 1020207037131 A KR1020207037131 A KR 1020207037131A KR 20207037131 A KR20207037131 A KR 20207037131A KR 102912248 B1 KR102912248 B1 KR 102912248B1
Authority
KR
South Korea
Prior art keywords
hpβcd
less
substance
ppm
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207037131A
Other languages
English (en)
Korean (ko)
Other versions
KR20210027279A (ko
Inventor
클로틸드 뷔페
조엘 델라트레
뱅상 비아츠
Original Assignee
로께뜨프레르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1855952A external-priority patent/FR3083234B1/fr
Application filed by 로께뜨프레르 filed Critical 로께뜨프레르
Publication of KR20210027279A publication Critical patent/KR20210027279A/ko
Application granted granted Critical
Publication of KR102912248B1 publication Critical patent/KR102912248B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
KR1020207037131A 2018-06-29 2019-06-28 신규 히드록시프로필-β-사이클로덱스트린 및 이의 제조 방법 Active KR102912248B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR1855952A FR3083234B1 (fr) 2018-06-29 2018-06-29 Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation
FR1855952 2018-06-29
FR1902375 2019-03-08
FR1902375 2019-03-08
PCT/FR2019/051602 WO2020002851A1 (fr) 2018-06-29 2019-06-28 NOUVELLE HYDROXYPROPYL-β-CYCLODEXTRINE ET SON PROCÉDÉ DE PRÉPARATION

Publications (2)

Publication Number Publication Date
KR20210027279A KR20210027279A (ko) 2021-03-10
KR102912248B1 true KR102912248B1 (ko) 2026-01-15

Family

ID=67551566

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207037131A Active KR102912248B1 (ko) 2018-06-29 2019-06-28 신규 히드록시프로필-β-사이클로덱스트린 및 이의 제조 방법

Country Status (10)

Country Link
US (1) US12522670B2 (https=)
EP (1) EP3814386A1 (https=)
JP (2) JP7581055B2 (https=)
KR (1) KR102912248B1 (https=)
CN (1) CN112334494A (https=)
CA (1) CA3104568A1 (https=)
IL (1) IL279845A (https=)
MX (1) MX2020013689A (https=)
SG (1) SG11202013126QA (https=)
WO (1) WO2020002851A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7607935B2 (ja) 2019-01-03 2025-01-06 サイクラリティ・セラピューティクス・インコーポレイテッド シクロデキストリン二量体、それらの組成物、及びそれらの使用
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
JP2024064599A (ja) * 2022-10-28 2024-05-14 国立大学法人 熊本大学 細胞内コレステロール輸送障害に起因する疾患又は障害の治療、予防又は改善用組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102040675A (zh) * 2010-12-22 2011-05-04 石药集团石家庄高科医药科技开发有限公司 一种羟丙基-β-环糊精的制备方法
CN108034010A (zh) * 2017-12-29 2018-05-15 山东滨州智源生物科技有限公司 一种羟丙基环糊精的绿色制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
HK1009335A1 (en) * 1989-04-03 1999-05-28 Janssen Pharmaceutica N.V. Regioselective substitutions in cyclodextrins
US5096893A (en) 1989-04-03 1992-03-17 The United States Of America As Represented By The Department Of Health And Human Services Regioselective substitutions in cyclodextrins
KR920008700A (ko) * 1990-10-29 1992-05-28 이헌조 데크의 테이프 삽입유무 표시방법
DE19505263A1 (de) * 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
CN1155888A (zh) * 1995-06-08 1997-07-30 火箭兄弟公司 粉状羟丙基-β-环糊精组合物和其制备方法
FR2735136B1 (fr) * 1995-06-08 1997-08-14 Roquette Freres Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
FR2738149B1 (fr) * 1995-09-06 1997-11-14 Chauvin Lab Sa Collyre a base d'indometacine pret a l'emploi
US5744154A (en) 1995-09-06 1998-04-28 Laboratoire Chauvin S.A. Ready-to-use indomethacin-based eye lotion
EP1655034A1 (en) 2004-10-10 2006-05-10 Université de Liège Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases.
WO2012037117A1 (en) 2010-09-13 2012-03-22 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
CN102558394B (zh) * 2010-12-07 2014-11-12 石药集团中奇制药技术（石家庄）有限公司 羟丙基-β-环糊精的制备方法
US8791269B2 (en) 2011-07-01 2014-07-29 Fondazione Istituto Insubrico Di Ricerca Per La Vita Complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
CA2988529A1 (en) 2015-06-10 2016-12-15 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102040675A (zh) * 2010-12-22 2011-05-04 石药集团石家庄高科医药科技开发有限公司 一种羟丙基-β-环糊精的制备方法
CN108034010A (zh) * 2017-12-29 2018-05-15 山东滨州智源生物科技有限公司 一种羟丙基环糊精的绿色制备方法

Also Published As

Publication number Publication date
US12522670B2 (en) 2026-01-13
EP3814386A1 (fr) 2021-05-05
JP2024150779A (ja) 2024-10-23
KR20210027279A (ko) 2021-03-10
IL279845A (en) 2021-03-01
JP2021529243A (ja) 2021-10-28
SG11202013126QA (en) 2021-02-25
JP7581055B2 (ja) 2024-11-12
US20210253746A1 (en) 2021-08-19
WO2020002851A1 (fr) 2020-01-02
MX2020013689A (es) 2021-05-12
CA3104568A1 (fr) 2020-01-02
CN112334494A (zh) 2021-02-05

Similar Documents

Publication Publication Date Title
JP2024150779A (ja) 新規なヒドロキシプロピル－β－シクロデキストリン及びそれを生成するための方法
JP3579060B2 (ja) アリール―複素環式化合物塩の包接錯体
FI86140B (fi) Foerfarande foer framstaellning av en farmaceutisk beredning som innehaoller ett i vatten svaorloesligt eller i vatten instabilt laekemedel.
EP2019664B1 (en) Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same
US20050222086A1 (en) Alprazolam inclusion complexes and pharmaceutical composition thereof
JP2005530866A (ja) 有機医薬とβ−シクロデキストリン誘導体との複合体、およびその調製方法
Das et al. Utility of Sulfobutyl Ether β-Cyclodextrin Inclusion Complexes in Drug Delivery: A Review.
Khan et al. Cyclodextrin: an overview
KR101731155B1 (ko) 안정화된 보리코나졸 조성물
US11098135B2 (en) Methylated cyclodextrins and methods for the production thereof
CN1879887B (zh) 基于水溶性环糊精聚合物的难溶性药物给药系统
US6077871A (en) Droloxifene pharmaceutical compositions
Kim et al. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-β-cyclodextrin
Lemesle-Lamache et al. Study of β-cyclodextrin and ethylated β-cyclodextrin salbutamol complexes, in vitro evaluation of sustained-release behaviour of salbutamol
JP4124483B2 (ja) ミセル様水性組成物及び疎水性薬物の可溶化方法
EP2529742B1 (en) Pharmaceutical composition comprising dapagliflozin and cyclodextrin
Arora et al. Physicochemical characterization and evaluation of telmisartan: hydroxypropyl-βcyclodextrin: Tween 80 inclusion complex
EP2943224B1 (en) Voriconazole inclusion complexes
Nie et al. In vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-β-cyclodextrin
Choudhary et al. A systematic review on cyclodextrin: a versatile tool for enhanced formulations and diverse applications
US20040242538A1 (en) Method to improve complexation efficacy and produce high-energy cylodextrincomplexes
VARGANICI et al. β-Cyclodextrin as carrier for different guest molecules in bioapplications–a minireview on the thermal complexation studies by differential scanning calorimetry
CN120242052A (zh) 一种甲苯咪唑HP-β-环糊精包合物及其制备方法
KR920008700B1 (ko) 수-난용성 또는 수-불안정성 약제와 β-사이클로덱스트린 에테르의 수용성 복합체의 제조방법
CN117159742A (zh) 一种随机甲基化β-环糊精酮康唑包合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)